Rajiv Leventhal
Analyst, Digital Health at EMARKETER
Senior Analyst, Digital Health @EMARKETER, covering the intersection of healthcare & tech & why it matters. Previously, Managing Editor @HCInnovationGrp
Articles
-
1 week ago |
emarketer.com | Rajiv Leventhal
The news: Oura is partnering with Maven Clinic to integrate smart ring data with providers’ care and treatment plans. For context, Maven provides virtual care for women’s and family health. Unpacking the news: Eligible patients who have an Oura Ring will have the option to sync data on sleep, stress, and activity with the Maven platform. Maven providers can then use this health tracking data to adjust their health guidance.
-
1 week ago |
emarketer.com | Rajiv Leventhal
The data: Nearly two-thirds of US adults (64%) have an unfavorable view of the House’s One Big Beautiful Bill Act, per KFF polling this week. 1,321 US adults were surveyed earlier this month. Catch up quick: The House’s version of the tax and budget reconciliation bill that the Senate is currently considering has potentially significant implications for healthcare.
-
1 week ago |
emarketer.com | Rajiv Leventhal
The news: Anne Wojcicki, the co-founder and former CEO of 23andMe, is set to recoup control of the company after outbidding Regeneron Pharmaceuticals in a bankruptcy auction. The final price of $305 million, which topped Regeneron’s previous bid of $265 million, is being paid by Wojcicki via a nonprofit public benefit corporation that she created called the TTAM Research Institute. A court will still need to give final approval of the deal.
-
2 weeks ago |
emarketer.com | Rajiv Leventhal
The news: Eli Lilly said it won’t partner with telehealth companies that sell compounded weight loss drugs. It referred to compounding as “breaking the law” in a statement to Yahoo Finance. For context, Lilly and rival Novo Nordisk recently let a range of telehealth providers sell their name-brand GLP-1s at a discount to people without insurance coverage.
-
2 weeks ago |
emarketer.com | Rajiv Leventhal
The news: GoodRx is rolling out a subscription service for erectile dysfunction (ED) treatment. More on the offering: Subscriptions start at $18 per month for sildenafil (generic Viagra) or $21 per month for tadalafil (generic Cialis). However, consumers could end up paying around $100 a month, depending on how many doses of the drug they want. GoodRx will connect consumers with a telehealth provider who can prescribe the medication.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 3K
- Tweets
- 12K
- DMs Open
- No
RT @daveyalba: NEW with @ikeswetlitz: Google’s parent company spent billions on failed health projects. Will healthcare AI be its saving gr…
RT @GabrielSPerna: Dang $230M. That says it all. Publicly traded retail company will never stand for those kinds of losses.
RT @Law360: In the wake of major closure announcements by Walgreens and Walmart, some experts see signs of a larger retreat in brick-and-mo…